May 27, 2014
GlaxoSmithKline (GSK) said on May 23 that it has filed its long-acting muscarinic antagonist umeclidinium for approval for an indication of chronic obstructive pulmonary disease (COPD) in Japan. Umeclidinium is expected to improve breathing functions and remit respiratory symptoms associated...read more